Zoom: https://mc-meet.zoom.us/j/94815357743?pwd=SmZlWFFlYVB0anlsRlRPQjNieFI3dz09

Meeting ID: 9480153507743
Passcode: 851751

Virtual Visiting Faculty
Ashley Aaroe, M.D.
MD Anderson Cancer Center
"Erdheim-Chester Disease"

Learning objectives
Upon conclusion of this activity, participants will be able to:

• Review the neurological manifestations associated with Erdhiem-Chester Disease (ECD)
• Summarize various treatment modalities used in ECD and data supporting the use of BRAF and MEK-Inhibitors

The presenter (nor spouse/partner) does not have a relevant financial relationship to disclose. She does intend to discuss off-label/investigative uses of the following commercial products/devices: Novartis - Trametinib (and MEK-inhibitors as a drug class).

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.